Skip to main content
Top
Published in: Inflammation 6/2015

01-12-2015

Fusion Peptides CPU1 and CPU2 Inhibit Matrix Metalloproteinases and Protect Mice from Endotoxin Shock Within a Strict Time Window

Authors: Zheng Qiu, Fengguo Zhang, Chengxin Gong, Hanmei Xu, Jialiang Hu

Published in: Inflammation | Issue 6/2015

Login to get access

Abstract

Endotoxin shock induction in mice is a commonly used animal model to evaluate the protective effect of biologically active reagents. After an lipopolysaccharides (LPS) stimulus, matrix metalloproteinase-8 (MMP-8) and matrix metalloproteinase-9 (MMP-9) are rapidly degranulated and released by neutrophils, aside other enzymes and effector molecules. MMPs cleave extracellular matrix components and cytokines, and such processes contribute to shock syndrome development. CPU1 and CPU2 are two peptide MMP inhibitors with different in vitro IC50 values to several key enzymes, including MMP-8 and MMP-9. In vivo work confirmed that CPU1 and CPU2 protected mice from endotoxin shock after intravenous and intraperitoneal injections. Furthermore, their minimal effective dose after an intravenous injection and the maximum time interval between intraperitoneal peptide injection (150 mg/kg) and intravenous LPS injection were determined. With the use of an indirect competitive ELISA, plasma CPU1 and CPU2 concentrations in different experimental settings were measured. In addition, the acuteness of MMP-9 release in the mouse circulation after an intravenous LPS injection was confirmed with the zymography technique. Our findings reinforce previous work with other inhibitors about a strict time window within which effective MMP inhibition is needed to obtain significant survival rate improvements and also show that, with strict pharmacokinetic monitoring, potent protease inhibitors may in the future become life-savers in shock conditions.
Literature
2.
go back to reference Parrillo, J.E. 1993. Mechanisms of disease: pathogenetic mechanisms of septic shock. New England Journal of Medicine 328: 1471–1417.CrossRefPubMed Parrillo, J.E. 1993. Mechanisms of disease: pathogenetic mechanisms of septic shock. New England Journal of Medicine 328: 1471–1417.CrossRefPubMed
3.
go back to reference Beutler, B. 2002. Toll-like receptors: how they work and what they do. Current Opinion in Hematology 9: 2–10.CrossRefPubMed Beutler, B. 2002. Toll-like receptors: how they work and what they do. Current Opinion in Hematology 9: 2–10.CrossRefPubMed
4.
go back to reference Hoshino, K., O. Takeuchi, T. Kawai, H. Sanjo, T. Ogawa, Y. Takeda, K. Takeda, and S. Akira. 1999. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. Journal of Immunology 162: 3749–3752. Hoshino, K., O. Takeuchi, T. Kawai, H. Sanjo, T. Ogawa, Y. Takeda, K. Takeda, and S. Akira. 1999. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. Journal of Immunology 162: 3749–3752.
5.
go back to reference Rothe, J., W. Lesslauer, H. Lotscher, Y. Lang, P. Koebel, F. Kontgen, A. Althage, R. Zinkernagel, M. Steinmetz, and H. Bluethmann. 1993. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 364: 798–802.CrossRefPubMed Rothe, J., W. Lesslauer, H. Lotscher, Y. Lang, P. Koebel, F. Kontgen, A. Althage, R. Zinkernagel, M. Steinmetz, and H. Bluethmann. 1993. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 364: 798–802.CrossRefPubMed
6.
go back to reference Pfeffer, K., T. Matsuyama, T.M. Kundig, A. Wakeham, K. Kishihara, A. Shahinian, K. Wiegmann, P.S. Ohashi, M. Kronke, and T.W. Mak. 1993. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 73: 457–467.CrossRefPubMed Pfeffer, K., T. Matsuyama, T.M. Kundig, A. Wakeham, K. Kishihara, A. Shahinian, K. Wiegmann, P.S. Ohashi, M. Kronke, and T.W. Mak. 1993. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 73: 457–467.CrossRefPubMed
7.
go back to reference Car, B.D., V.M. Eng, B. Schnyder, L. Ozmen, S. Huang, P. Gallay, D. Heumann, M. Aguet, and B. Ryffel. 1994. Interferon gamma receptor deficient mice are resistant to endotoxic shock. Journal of Experimental Medicine 179: 1437–1444.CrossRefPubMed Car, B.D., V.M. Eng, B. Schnyder, L. Ozmen, S. Huang, P. Gallay, D. Heumann, M. Aguet, and B. Ryffel. 1994. Interferon gamma receptor deficient mice are resistant to endotoxic shock. Journal of Experimental Medicine 179: 1437–1444.CrossRefPubMed
8.
go back to reference Riedemann, N.C., R.F. Guo, K.D. Bernacki, J.S. Reuben, I.J. Laudes, T.A. Neff, H. Gao, C. Speyer, V.J. Sarma, F.S. Zetoune, and P.A. Ward. 2003. Regulation by C5a of neutrophil activation during sepsis. Immunity 19: 193–202.CrossRefPubMed Riedemann, N.C., R.F. Guo, K.D. Bernacki, J.S. Reuben, I.J. Laudes, T.A. Neff, H. Gao, C. Speyer, V.J. Sarma, F.S. Zetoune, and P.A. Ward. 2003. Regulation by C5a of neutrophil activation during sepsis. Immunity 19: 193–202.CrossRefPubMed
9.
go back to reference Dubois, B., S. Starckx, A. Pagenstecher, J. van den Oord, B. Arnold, and G. Opdenakker. 2002. Gelatinase B deficiency protects against endotoxin shock. European Journal of Immunology 32: 2163–2171.CrossRefPubMed Dubois, B., S. Starckx, A. Pagenstecher, J. van den Oord, B. Arnold, and G. Opdenakker. 2002. Gelatinase B deficiency protects against endotoxin shock. European Journal of Immunology 32: 2163–2171.CrossRefPubMed
10.
go back to reference Abraham, E., M.R. Gyetko, K. Kuhn, J. Arcaroli, D. Strassheim, J.S. Park, S. Shetty, and S. Idell. 2003. Urokinase-type plasminogen activator potentiates lipopolysaccharide-induced neutrophil activation. Journal of Immunology 170: 5644–5651.CrossRef Abraham, E., M.R. Gyetko, K. Kuhn, J. Arcaroli, D. Strassheim, J.S. Park, S. Shetty, and S. Idell. 2003. Urokinase-type plasminogen activator potentiates lipopolysaccharide-induced neutrophil activation. Journal of Immunology 170: 5644–5651.CrossRef
11.
go back to reference Barrett, A.J., N.D. Rawlings, and J.F. Woessner. 2004. Handbook of Proteolytic enzymes (second edition). London: Elsevier Academic Press. Barrett, A.J., N.D. Rawlings, and J.F. Woessner. 2004. Handbook of Proteolytic enzymes (second edition). London: Elsevier Academic Press.
12.
go back to reference Sternlicht, M.D., and Z. Werb. 2001. How matrix metalloproteinases regulate cell behavior. Annual Review of Cell and Developmental Biology 17: 463–516.PubMedCentralCrossRefPubMed Sternlicht, M.D., and Z. Werb. 2001. How matrix metalloproteinases regulate cell behavior. Annual Review of Cell and Developmental Biology 17: 463–516.PubMedCentralCrossRefPubMed
13.
go back to reference Overall, C.M., and C. Lopez-Otin. 2002. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nature Reviews Cancer 2: 657–672.CrossRefPubMed Overall, C.M., and C. Lopez-Otin. 2002. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nature Reviews Cancer 2: 657–672.CrossRefPubMed
14.
go back to reference Qiu, Z., J. Hu, P.E. Van den Steen, and G. Opdenakker. 2012. Targeting matrix metalloproteinases in acute inflammatory shock syndromes. Combinatorial Chemistry & High Throughput Screening 15: 555–570.CrossRef Qiu, Z., J. Hu, P.E. Van den Steen, and G. Opdenakker. 2012. Targeting matrix metalloproteinases in acute inflammatory shock syndromes. Combinatorial Chemistry & High Throughput Screening 15: 555–570.CrossRef
15.
go back to reference Pfefferkorn, T., and G.A. Rosenberg. 2003. Closure of the blood-brain barrier by matrix metalloproteinase inhibition reduces rtPA-mediated mortality in cerebral ischemia with delayed reperfusion. Stroke 34: 2025–2030.CrossRefPubMed Pfefferkorn, T., and G.A. Rosenberg. 2003. Closure of the blood-brain barrier by matrix metalloproteinase inhibition reduces rtPA-mediated mortality in cerebral ischemia with delayed reperfusion. Stroke 34: 2025–2030.CrossRefPubMed
16.
go back to reference Rosenberg, G.A., E.Y. Estrada, and S. Mobashery. 2007. Effect of synthetic matrix metalloproteinase inhibitors on lipopolysaccharide-induced blood-brain barrier opening in rodents: differences in response based on strains and solvents. Brain Research 1133: 186–192.PubMedCentralCrossRefPubMed Rosenberg, G.A., E.Y. Estrada, and S. Mobashery. 2007. Effect of synthetic matrix metalloproteinase inhibitors on lipopolysaccharide-induced blood-brain barrier opening in rodents: differences in response based on strains and solvents. Brain Research 1133: 186–192.PubMedCentralCrossRefPubMed
17.
go back to reference Solorzano, C.C., R. Ksontini, J.H. Pruitt, T. Auffenberg, C. Tannahill, R.E. Galardy, G.P. Schultz, S.L. MacKay, E.M. Copeland, and L.L. Moldawer. 1997. A matrix metalloproteinase inhibitor prevents processing of tumor necrosis factor alpha (TNF alpha) and abrogates endotoxin-induced lethality. Shock 7: 427–431.CrossRefPubMed Solorzano, C.C., R. Ksontini, J.H. Pruitt, T. Auffenberg, C. Tannahill, R.E. Galardy, G.P. Schultz, S.L. MacKay, E.M. Copeland, and L.L. Moldawer. 1997. A matrix metalloproteinase inhibitor prevents processing of tumor necrosis factor alpha (TNF alpha) and abrogates endotoxin-induced lethality. Shock 7: 427–431.CrossRefPubMed
18.
go back to reference Paemen, L., E. Martens, K. Norga, S. Masure, E. Roets, J. Hoogmartens, and G. Opdenakker. 1996. The gelatinase inhibitory activity of tetracyclines and chemically modified tetracycline analogues as measured by a novel microtiter assay for inhibitors. Biochemical Pharmacology 52: 105–111.CrossRefPubMed Paemen, L., E. Martens, K. Norga, S. Masure, E. Roets, J. Hoogmartens, and G. Opdenakker. 1996. The gelatinase inhibitory activity of tetracyclines and chemically modified tetracycline analogues as measured by a novel microtiter assay for inhibitors. Biochemical Pharmacology 52: 105–111.CrossRefPubMed
19.
go back to reference Shapira, L., W.A. Soskolne, Y. Houri, V. Barak, A. Halabi, and A. Stabholz. 1996. Protection against endotoxic shock and lipopolysaccharide-induced local inflammation by tetracycline: correlation with inhibition of cytokine secretion. Infection and Immunity 64: 825–828.PubMedCentralPubMed Shapira, L., W.A. Soskolne, Y. Houri, V. Barak, A. Halabi, and A. Stabholz. 1996. Protection against endotoxic shock and lipopolysaccharide-induced local inflammation by tetracycline: correlation with inhibition of cytokine secretion. Infection and Immunity 64: 825–828.PubMedCentralPubMed
20.
go back to reference Ramamurthy, N.S., B.R. Rifkin, R.A. Greenwald, J.W. Xu, Y. Liu, G. Turner, L.M. Golub, and A.T. Vernillo. 2002. Inhibition of matrix metalloproteinase-mediated periodontal bone loss in rats: a comparison of 6 chemically modified tetracyclines. Journal of Periodontology 73: 726–734.CrossRefPubMed Ramamurthy, N.S., B.R. Rifkin, R.A. Greenwald, J.W. Xu, Y. Liu, G. Turner, L.M. Golub, and A.T. Vernillo. 2002. Inhibition of matrix metalloproteinase-mediated periodontal bone loss in rats: a comparison of 6 chemically modified tetracyclines. Journal of Periodontology 73: 726–734.CrossRefPubMed
21.
go back to reference Krüger, A., R.E. Kates, and D.R. Edwards. 2010. Avoiding spam in the proteolytic internet: future strategies for anti-metastatic MMP inhibition. Biochimica et Biophysica Acta 1803: 95–102.CrossRefPubMed Krüger, A., R.E. Kates, and D.R. Edwards. 2010. Avoiding spam in the proteolytic internet: future strategies for anti-metastatic MMP inhibition. Biochimica et Biophysica Acta 1803: 95–102.CrossRefPubMed
22.
go back to reference Weiss, S.J. 1989. Tissue destruction by neutrophils. New England Journal of Medicine 320: 365–376.CrossRefPubMed Weiss, S.J. 1989. Tissue destruction by neutrophils. New England Journal of Medicine 320: 365–376.CrossRefPubMed
23.
go back to reference Paemen, L., P.M. Jansen, P. Proost, J. Van Damme, G. Opdenakker, E. Hack, and F.B. Taylor. 1997. Induction of gelatinase B and MCP-2 in baboons during sublethal and lethal bacteraemia. Cytokine 9: 412–415.CrossRefPubMed Paemen, L., P.M. Jansen, P. Proost, J. Van Damme, G. Opdenakker, E. Hack, and F.B. Taylor. 1997. Induction of gelatinase B and MCP-2 in baboons during sublethal and lethal bacteraemia. Cytokine 9: 412–415.CrossRefPubMed
24.
go back to reference Pugin, J., M.C. Widmer, S. Kossodo, C.M. Liang, H.L. Preas, and A.F. Suffredini. 1999. Human neutrophils secrete gelatinase B in vitro and in vivo in response to endotoxin and proinflammatory mediators. American Journal of Respiratory Cell and Molecular Biology 20: 458–464.CrossRefPubMed Pugin, J., M.C. Widmer, S. Kossodo, C.M. Liang, H.L. Preas, and A.F. Suffredini. 1999. Human neutrophils secrete gelatinase B in vitro and in vivo in response to endotoxin and proinflammatory mediators. American Journal of Respiratory Cell and Molecular Biology 20: 458–464.CrossRefPubMed
25.
go back to reference Hu, J., P. Fiten, P.E. Van den Steen, P. Chaltin, and G. Opdenakker. 2005. Simulation of evolution-selected propeptide by high-throughput selection of a peptidomimetic inhibitor on a capillary DNA sequencer platform. Analytical Chemistry 77: 2116–2124.CrossRefPubMed Hu, J., P. Fiten, P.E. Van den Steen, P. Chaltin, and G. Opdenakker. 2005. Simulation of evolution-selected propeptide by high-throughput selection of a peptidomimetic inhibitor on a capillary DNA sequencer platform. Analytical Chemistry 77: 2116–2124.CrossRefPubMed
26.
go back to reference Hu, J., V. Dubois, P. Chaltin, P. Fiten, C. Dillen, P.E. Van den Steen, and G. Opdenakker. 2006. Inhibition of lethal endotoxin shock with an L-pyridylalanine containing metalloproteinase inhibitor selected by high-throughput screening of a new peptide library. Combinatorial Chemistry & High Throughput Screening 9: 599–611.CrossRef Hu, J., V. Dubois, P. Chaltin, P. Fiten, C. Dillen, P.E. Van den Steen, and G. Opdenakker. 2006. Inhibition of lethal endotoxin shock with an L-pyridylalanine containing metalloproteinase inhibitor selected by high-throughput screening of a new peptide library. Combinatorial Chemistry & High Throughput Screening 9: 599–611.CrossRef
27.
go back to reference Hu, J., P.E. Van den Steen, C. Dillen, and G. Opdenakker. 2005. Targeting neutrophil collagenase/matrix metalloproteinase-8 and gelatinase B/matrix metalloproteinase-9 with a peptidomimetic inhibitor protects against endotoxin shock. Biochemical Pharmacology 70: 535–544.CrossRefPubMed Hu, J., P.E. Van den Steen, C. Dillen, and G. Opdenakker. 2005. Targeting neutrophil collagenase/matrix metalloproteinase-8 and gelatinase B/matrix metalloproteinase-9 with a peptidomimetic inhibitor protects against endotoxin shock. Biochemical Pharmacology 70: 535–544.CrossRefPubMed
28.
go back to reference Hu, J., M. Yan, C. Pu, J. Wang, P.E. Van den Steen, G. Opdenakker, and H. Xu. 2014. Chemically synthesized matrix metalloproteinase and angiogenesis-inhibiting peptides as anticancer agents. Anti-Cancer Agents in Medicinal Chemistry 14: 483–494.CrossRefPubMed Hu, J., M. Yan, C. Pu, J. Wang, P.E. Van den Steen, G. Opdenakker, and H. Xu. 2014. Chemically synthesized matrix metalloproteinase and angiogenesis-inhibiting peptides as anticancer agents. Anti-Cancer Agents in Medicinal Chemistry 14: 483–494.CrossRefPubMed
29.
go back to reference Wickström, S.A., K. Alitalo, and J. Keski-Oja. 2004. An endostatin-derived peptide interacts with integrins and regulates actin cytoskeleton and migration of endothelial cells. Journal of Biological Chemistry 279: 20178–20185.CrossRefPubMed Wickström, S.A., K. Alitalo, and J. Keski-Oja. 2004. An endostatin-derived peptide interacts with integrins and regulates actin cytoskeleton and migration of endothelial cells. Journal of Biological Chemistry 279: 20178–20185.CrossRefPubMed
30.
go back to reference Knight, C.G., F. Willenbrock, and G. Murphy. 1992. A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases. FEBS Letters 296: 263–266.CrossRefPubMed Knight, C.G., F. Willenbrock, and G. Murphy. 1992. A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases. FEBS Letters 296: 263–266.CrossRefPubMed
31.
go back to reference Hu, J., P.E. Van den Steen, M. Houde, T.T. Ilenchuk, and G. Opdenakker. 2004. Inhibitors of gelatinase B/matrix metalloproteinase-9 activity comparison of a peptidomimetic and polyhistidine with single-chain derivatives of a neutralizing monoclonal antibody. Biochemical Pharmacology 67: 1001–1009.CrossRefPubMed Hu, J., P.E. Van den Steen, M. Houde, T.T. Ilenchuk, and G. Opdenakker. 2004. Inhibitors of gelatinase B/matrix metalloproteinase-9 activity comparison of a peptidomimetic and polyhistidine with single-chain derivatives of a neutralizing monoclonal antibody. Biochemical Pharmacology 67: 1001–1009.CrossRefPubMed
32.
go back to reference Paemen, L., E. Martens, S. Masure, and G. Opdenakker. 1995. Monoclonal antibodies specific for natural human neutrophil gelatinase B used for affinity purification, quantitation by two-site ELISA and inhibition of enzymatic activity. European Journal of Biochemistry 234: 759–765.CrossRefPubMed Paemen, L., E. Martens, S. Masure, and G. Opdenakker. 1995. Monoclonal antibodies specific for natural human neutrophil gelatinase B used for affinity purification, quantitation by two-site ELISA and inhibition of enzymatic activity. European Journal of Biochemistry 234: 759–765.CrossRefPubMed
33.
go back to reference Granelli-Piperno, A., and E. Reich. 1978. A study of proteases and protease-inhibitor complexes in biological fluids. Journal of Experimental Medicine 148: 223–234.PubMedCentralCrossRefPubMed Granelli-Piperno, A., and E. Reich. 1978. A study of proteases and protease-inhibitor complexes in biological fluids. Journal of Experimental Medicine 148: 223–234.PubMedCentralCrossRefPubMed
34.
go back to reference Vandooren, J., N. Geurts, E. Martens, P.E. Van den Steen, and G. Opdenakker. 2013. Zymography methods for visualizing hydrolytic enzymes. Nature Methods 10: 211–220.CrossRefPubMed Vandooren, J., N. Geurts, E. Martens, P.E. Van den Steen, and G. Opdenakker. 2013. Zymography methods for visualizing hydrolytic enzymes. Nature Methods 10: 211–220.CrossRefPubMed
35.
go back to reference Qiu, Z., Chen, J., Xu, H., Van den Steen, P. E., Opdenakker, G., Wang, M., Hu, J. (2014) Inhibition of neutrophil collagenase/MMP-8 and gelatinase B/MMP-9 and protection against endotoxin shock. Journal of Immunological Research. doi:10.1155/2014/747426. Qiu, Z., Chen, J., Xu, H., Van den Steen, P. E., Opdenakker, G., Wang, M., Hu, J. (2014) Inhibition of neutrophil collagenase/MMP-8 and gelatinase B/MMP-9 and protection against endotoxin shock. Journal of Immunological Research. doi:10.​1155/​2014/​747426.
36.
go back to reference Descamps, F.J., E. Martens, and G. Opdenakker. 2002. Analysis of gelatinases in complex biological fluids and tissue extracts. Laboratory Investigation 82: 1607–1608.CrossRefPubMed Descamps, F.J., E. Martens, and G. Opdenakker. 2002. Analysis of gelatinases in complex biological fluids and tissue extracts. Laboratory Investigation 82: 1607–1608.CrossRefPubMed
37.
go back to reference Opdenakker, G., I. Nelissen, and J. Van Damme. 2003. Functional roles and therapeutic targeting of gelatinase B and chemokines in multiple sclerosis. Lancet Neurology 2: 747–756.CrossRefPubMed Opdenakker, G., I. Nelissen, and J. Van Damme. 2003. Functional roles and therapeutic targeting of gelatinase B and chemokines in multiple sclerosis. Lancet Neurology 2: 747–756.CrossRefPubMed
38.
go back to reference Van Wart, H.E., and H. Birkedal-Hansen. 1990. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proceedings of the National academy of Sciences of the United States of America 87: 5578–5582.PubMedCentralCrossRefPubMed Van Wart, H.E., and H. Birkedal-Hansen. 1990. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proceedings of the National academy of Sciences of the United States of America 87: 5578–5582.PubMedCentralCrossRefPubMed
39.
go back to reference Masure, S., P. Proost, J. Van Damme, and G. Opdenakker. 1991. Purification and identification of 91-kDa neutrophil gelatinase. Release by the activating peptide interleukin-8. European Journal of Biochemistry 198: 391–398.CrossRefPubMed Masure, S., P. Proost, J. Van Damme, and G. Opdenakker. 1991. Purification and identification of 91-kDa neutrophil gelatinase. Release by the activating peptide interleukin-8. European Journal of Biochemistry 198: 391–398.CrossRefPubMed
40.
go back to reference Masure, S., L. Paemen, I. Van Aelst, P. Fiten, P. Proost, A. Billiau, J. Van Damme, and G. Opdenakker. 1997. Production and characterization of recombinant active mouse gelatinase B from eukaryotic cells and in vivo effects after intravenous administration. European Journal of Biochemistry 244: 21–30.CrossRefPubMed Masure, S., L. Paemen, I. Van Aelst, P. Fiten, P. Proost, A. Billiau, J. Van Damme, and G. Opdenakker. 1997. Production and characterization of recombinant active mouse gelatinase B from eukaryotic cells and in vivo effects after intravenous administration. European Journal of Biochemistry 244: 21–30.CrossRefPubMed
Metadata
Title
Fusion Peptides CPU1 and CPU2 Inhibit Matrix Metalloproteinases and Protect Mice from Endotoxin Shock Within a Strict Time Window
Authors
Zheng Qiu
Fengguo Zhang
Chengxin Gong
Hanmei Xu
Jialiang Hu
Publication date
01-12-2015
Publisher
Springer US
Published in
Inflammation / Issue 6/2015
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-015-0192-3

Other articles of this Issue 6/2015

Inflammation 6/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.